Project Grant R01MD019038
Award Date
8/28/24
Completion Date
6/30/25
Dollars Obligated
$4M
Similar Awards
This $157,744 Project Grant award from the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program will fund a research project to develop and pilot an intervention to increase human papillomavirus (HPV) vaccination coverage among rural adolescents in North Carolina. The key objectives are to: 1) define optimal systems for recommending HPV vaccination at age 9 in rural clinics; 2) assess acceptability of age-9 HPV...
The National Cancer Institute (NCI) awarded a $233,411 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Pennsylvania State University's Milton S. Hershey Medical Center. The grant, titled "STORIES TO PREVENT (STOP) HPV CANCERS: A COMMUNICATION INTERVENTION TO INCREASE HPV VACCINATION AMONG DIVERSE POPULATIONS", aims to evaluate the impact of a narrative communication intervention delivered through digital and mobile technology on HPV vaccine...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $176,534 to Oregon Health & Science University (OHSU) from August 1, 2024 to July 31, 2029. The goals of the research are to: (1) describe cervical cancer screening rates among middle to older age Mexican immigrants at a 23-state network of community health centers (CHCs) from 2012-2023; (2) examine individual, organizational, and structural barriers to cervical cancer...
This $753,446 Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) aims to adapt and test an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations: urban inner city Blacks/Haitians in Boston, Hispanic immigrants in Florida, and Hawaiian Natives/Pacific Islanders in Hawaii. The intervention combines education and quality improvement methods using a mechanism called Performance...
This federal Project Grant award of $533,707, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how the human papillomavirus (HPV) evades the body's natural defenses and persists in infected cells. The primary goal is to elucidate the mechanism by which the HPV E7 oncoprotein activates the YAP1 signaling pathway, enabling HPV-infected cells to remain in the...
The federal Project Grant award, with ID IAHAH000001, was provided by the Centers for Disease Control and Prevention (CDC) under the Cooperative Agreements to Promote Adolescent Health through School-Based HIV/STD Prevention and School-Based Surveillance program (CFDA 93.079). The $1,999,710 award, made on September 30, 2024, supports policy research to improve the health and well-being of adolescents by addressing HIV, STDs, teen pregnancy, substance use, violence, and mental health through...
This Project Grant award from the National Institute on Minority Health and Health Disparities (NIMHD), under the Minority Health and Health Disparities Research program (CFDA 93.307), provides $781,238 to the University of California, San Francisco (UCSF) to conduct a 4-year mixed methods study. The study aims to: 1) describe current trends in school-based health center (SBHC) staffing models and practices nationally and create a classification system to strengthen future research, design,...
This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports the development and testing of a culturally-relevant digital health intervention targeting HPV vaccination among the U.S. Vietnamese population. The total award is $191,700 and will be completed by December 31, 2029. The key products and services to be delivered include: Assessing the feasibility and acceptability of four digital intervention components...
This Project Grant award of $3,381,578.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how human papillomavirus (HPV) proteins reprogram host cell signaling pathways. The research aims to determine how the degradation of the RB1 and PTPN14 tumor suppressors by high-risk HPV E7 proteins contributes to host cell reprogramming and cellular transformation. The award...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,837,497 to New York University to conduct the KUPEWA project. The project aims to (A) identify optimal implementation strategies for increasing clinician recommendation of HPV vaccination for girls and young women aged 9-24 living with HIV in Malawi, (B) refine these strategies based on implementability, and (C) identify strategies that are effective,...